{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:44:08Z","timestamp":1787618648463,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"intramural research program of NCI\/NIH","award":["1ZIABC010476-15"],"award-info":[{"award-number":["1ZIABC010476-15"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejca.2019.04.023","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T22:02:52Z","timestamp":1558735372000},"page":"111-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy\u00a0in Cancer Therapy Evaluation Program\u2013sponsored phase I trials"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2496-5283","authenticated-orcid":false,"given":"Shun","family":"Kishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobu","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Rinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali C.","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.04.023_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): an update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2019.04.023_bib2","series-title":"Symptoms: chemotherapy-induced peripheral neuropathy","first-page":"77","author":"Schneider","year":"2015"},{"key":"10.1016\/j.ejca.2019.04.023_bib3","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1523\/JNEUROSCI.0523-07.2007","article-title":"Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy","volume":"27","author":"Dzagnidze","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.ejca.2019.04.023_bib4","first-page":"657","article-title":"Chemotherapy-induced peripheral neurotoxicity","volume":"vol. 6","author":"Cavaletti","year":"2010"},{"key":"10.1016\/j.ejca.2019.04.023_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.04.023_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies","volume":"44","author":"Wolf","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.04.023_bib7","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.ejca.2019.04.023_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrneurol.2010.160","article-title":"Chemotherapy-induced peripheral neurotoxicity","volume":"6","author":"Cavaletti","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ejca.2019.04.023_bib9","first-page":"4","article-title":"Management of chemotherapy-induced peripheral neuropathy","volume":"11","author":"Trivedi","year":"2015","journal-title":"Am J Hematol\/Oncol"},{"key":"10.1016\/j.ejca.2019.04.023_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-009-0586-0","article-title":"Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy","volume":"119","author":"Shemesh","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2019.04.023_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1517\/14740338.2015.1056777","article-title":"Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives","volume":"14","author":"Poupon","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejca.2019.04.023_bib18","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-09-1961","article-title":"Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer Institute investigational drug steering committee","volume":"16","author":"Ivy","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.04.023_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.04.023_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/gyno.1996.0090","article-title":"The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer","volume":"61","author":"Gogas","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2019.04.023_bib21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","article-title":"Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies","volume":"35","author":"Chaudhry","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ejca.2019.04.023_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/gyno.1996.0090","article-title":"The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer","volume":"61","author":"Gogas","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2019.04.023_bib23","article-title":"Neurotoxicity of taxol","volume":"107\u201315","author":"Rowinsky","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejca.2019.04.023_bib24","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (Taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2019.04.023_bib25","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2010.31.9236","article-title":"Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?","volume":"29","author":"Postel-Vinay","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.04.023_bib26","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2014.04.031","article-title":"Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents \u2013 dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of T","volume":"50","author":"Postel-Vinay","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.04.023_bib27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/cncr.29918","article-title":"Beyond the dose-limiting toxicity period: dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program","volume":"122","author":"Drilon","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.04.023_bib28","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","article-title":"Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility","volume":"16","author":"Park","year":"2011","journal-title":"Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T17:49:53Z","timestamp":1608054593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919302771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":22,"alternative-id":["S0959804919302771"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.04.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy\u00a0in Cancer Therapy Evaluation Program\u2013sponsored phase I trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}